Paxlovid, which mixes nirmatrelvir and ritonavir in a pill, would require a prescription,
Mexican well being regulator COFEPRIS stated on Friday, January 15, 2022, it had authorised U.S. pharmaceutical firm Pfizer’s antiviral oral therapy in opposition to COVID-19 for emergency use in adults with gentle or reasonable threat of problems.
Paxlovid, which mixes nirmatrelvir and ritonavir in a pill, would require a prescription, it stated in an announcement.
The therapy was almost 90% efficient in stopping hospitalisations and deaths, and knowledge urged it retains itseffectiveness in opposition to the Omicron variant, Pfizer has stated.
Late final 12 months, COFEPRIS had authorised an identical therapy by Eli Lilly and Co.